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Abstract
The tyrosine kinase (TK) inhibitor (TKI) imatinib provides a highly effective treatment 
for chronic myeloid leukemia (CML) targeting at the causative oncogenic TK BCR-ABL1. 
However, imatinib exerts off-target effects by inhibiting other TKs that are involved, e.g., 
in bone metabolism. Clinically, CML patients on imatinib exhibit altered bone metabo-
lism as a side effect, which translates into linear growth failure in pediatric patients. As 
TKI treatment might be necessary for the whole life, long-term side effects exerted on 
bone and other developing organs in children are of major concern and not yet studied 
systematically. Here, we describe a new juvenile rat model to face this challenge. The 
established model mimics perfectly long-term side effects of TKI exposure on the grow-
ing bone in a developmental stage-dependent fashion. Thus, longitudinal growth impair-
ment observed clinically in children could be unequivocally modeled and confirmed. 
In a “bench-to-bedside” manner, we also demonstrate that this juvenile animal model 
predicts side effects of newer treatment strategies by second generation TKIs or modified 
treatment schedules (continuous vs. intermittent treatment) to minimize side effects. We 
conclude that the results generated by this juvenile animal model can be directly used in 
the clinic to optimize treatment algorithms in pediatric patients.
Keywords: juvenile, growth, bone, tyrosine kinase inhibitor, side effects, CML
1. Introduction
The introduction of tyrosine kinase inhibitors (TKIs) for targeted treatment of chronic myeloid 
leukemia (CML) marked a paradigm shift in the field of hemato-oncology [1, 2]. However, 
soon after CML became most successfully treated cancer—first in adults and thereafter in 
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children—it was learned that chronic exposure to TKIs impaired modeling of the osseous 
skeleton as an off-target effect [3]. This skeletal side effect resulted in impaired longitudinal 
growth in not outgrown minors [4, 5]. With regard to a potential lifelong necessity of TKI 
intake, children with CML differ from a typical patient with CML who is about 60 years old 
[6]. Thus, the rational of the research of TKIs’ off-target effects is to generate a clear picture of 
early and late sequelae of long-term drug intake.
On this background, the essential objective of this chapter is the description of a juvenile (still 
growing) rat model that allows a chronic administration of TKIs via the drinking water in 
order (i) to mimic osseous changes observed in humans, (ii) to further characterize and inves-
tigate the causative pathophysiologically mechanisms resulting in impaired bone growth, 
(iii) to test approaches in growing animals for ameliorating the off-target effect resulting in 
growth impairment, and (iv) to check further organs beside bone for long-term TKI toxicity.
In this chapter, sections describe i) the highly effective role that TKIs play in standardized 
attempts to operationally cure CML in adults as well as in children, ii) elucidate the role of the 
established juvenile male Wistar rat model to investigate with ease the skeletal changes at all 
developmental stages, and iii) focus on the administration of TKI via the drinking water over 
many weeks as an adequate and convenient way resulting in the achievement of therapeutic 
drug blood levels. TKI-induced changes in long bones, as well as vertebrae, can be investigated 
with dedicated small imaging devices while blood levels of bone turnover markers, growth hor-
mone, and vitamin D metabolites can be followed at different stages of development. The results 
of these investigations as well as  the derived hypothesis on the pathophysiological cascade, 
specifically how TKIs impair longitudinal bone growth, are in excellent agreement with clinical 
observations. In addition, the juvenile animal model is of value to monitor other long-term TKI 
side effects on the heart and fertility to generate an overall picture on all possible side effects.
2. Role of tyrosine kinase inhibitors in chronic myeloid leukemia treatment
The principal function of tyrosine kinases (TKs) involves the regulation of multicellular 
aspects of the organism. By transferring a γ-phosphate group from adenosine triphosphate 
(ATP) to the hydroxyl group of tyrosine residues on signal transduction molecules, cell-to-cell 
signals, including growth, differentiation, adhesion, motility, and death, are transmitted [7]. 
Around 90 TK genes have been identified in the human genome [8]. Based on kinase domain 
structure, 58 are of transmembrane receptor type and can be grouped into 20 subfamilies 
and 32 are of cytoplasmic non-receptor type which falls into 10 subfamilies [8, 9]. TK recep-
tors play a role in either transmembranous or intracellular signal transduction as they act as 
relay points controlling intracellular signaling pathways. Non-receptor TKs exhibit no trans-
membrane protein domain and are located in the cytoplasm. Generally, they are involved in 
signaling downstream of the receptor TKs.
In humans, TKs have been demonstrated to play significant roles in the development of many 
malignant diseases like chronic myeloid leukemia (CML) [8]. CML results from a recipro-
cal chromosomal translocation involving the c-abl proto-oncogene 1 (ABL1) on chromosome 
9 and the breakpoint cluster region (BCR) on chromosome 22, thus forming the BCR-ABL1 
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oncogene [10, 11]. This t(9; 22) translocation or Philadelphia chromosome (Ph+) is a charac-
teristic cytogenetic abnormality seen in 95% of patients with CML and in 15–30% of adult 
patients with acute lymphoblastic leukemia (ALL) [12, 13]. The BCR-ABL1 oncogene codes for 
two forms of fusion transcripts: p190BCR-ABL1 and p210BCR-ABL1, which are constitutively highly 
activated and subsequently dysregulate intracellular signaling by enhancing proliferative 
capability and resistance to apoptosis of hematopoietic stem or progenitor cells, leading to a 
massive increase in myeloid cell numbers.
About 1–1.5/100,000 residents are diagnosed with CML every year with an age peak between 
50 and 60 years [14], representing around 20% of all cases of leukemia in adulthood [15]. 
Concerning pediatric patients, the frequency of diagnosis is about 0.05–0.40/100,000 residents 
per year within the age of 0–18 years [16]. Thus, CML represents one of the rarest leukemic 
disorders in childhood and adolescent age, accounting for only 2–3% of all children suffer-
ing from leukemia [16]. In terms of morphological characteristics, childhood CML is not dif-
ferent from adult CML. However, it is a matter of an ongoing debate whether and to what 
extend molecular differences exist between CML diagnosed at childhood or older age [6]. For 
example, pediatric CML shows a breakpoint distribution in the BCR gene more similar to 
adult Ph+ ALL [17].
Still, as the BCR-ABL1 oncogene is the single molecular aberration causing the development 
of CML, specific TKIs like imatinib (Gleevec®, Novartis) have been developed to inhibit the 
BCR-ABL1 TK [19]. By achieving hematological and cytogenetic response in over 90% of the 
patients after a few months of imatinib treatment, imatinib has been very effective in inhibit-
ing progression of CML (Figure 1) [1, 20–23].
Figure 1. Survival probabilities by year of diagnosis (1980–2013) of pediatric patients with CML in Germany [18].
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However, some patients develop resistance to imatinib resulting in loss of treatment response or 
even leukemic relapse. Among other underlying mechanisms, BCR-ABL1 kinase domain muta-
tions can cause varying degrees of drug insensitivity [24]. In order to counter these mechanisms, 
next generation TKIs have been developed like dasatinib (SPRYCEL®, Bristol-Myers-Squibb), 
nilotinib (Tasigna®, Novartis), bosutinib (BOSULIF®, Pfizer), and ponatinib (ICLUSIG®, Ariad 
Pharmaceuticals) with different affinities to the ATP-binding pocket of the BCR-ABL1 TK [25].
3. Imatinib as front-line treatment for pediatric CML
As imatinib has proven very effective in adult CML, its accelerated clinical approval was given 
in the year 2001 for adults with CML and without age restriction in 2003. In several studies, ima-
tinib showed similar antileukemic efficacy in children compared to adults (Figure 1) [26, 27]. 
Typically, standard dose of imatinib (300 mg/m2) achieved a complete hematologic remission 
in 95% of the pediatric patients after 3 months, a complete cytogenetic remission in 80% after 12 
months, and a major molecular remission (MR3.0 = 0.1 % ratio copy number of gene transcripts 
BCR-ABL1/control gene) in 60% after 18 months of treatment [16, 28].
Although imatinib acts relatively specifically against the dysregulated BCR-ABL1 TK, it is 
known that imatinib exerts off-target effects at therapeutic blood levels on other TKs (Table 1). 
The reason for this is the affinity of imatinib to the ATP-binding pocket of the kinase domain. 
This domain is a characteristic feature of many members of the kinome, including TKs (review 
of the human kinome: [29, 30], review structure of the TK: [8, 9]).
Nevertheless, imatinib treatment is generally well tolerated, showing mostly mild side effects. 
Neutropenia, thrombocytopenia, and anemia occur in up to 45, 20, and 10% of patients, 
respectively, who are in the chronic phase of CML and receive standard dose imatinib [2]. 
Nonhematologic adverse effects include nausea, skin rashes, peripheral edemas, muscle 
cramps, and elevated liver transaminase levels [2].
Studies with imatinib in adult patients also showed disturbed bone metabolism as a specific 
side effect [3] comprising altered calcium metabolism as well as increased trabecular min-
eralization and increased bone density in stamp biopsies [32]. In children, imatinib therapy 
has been associated with severe longitudinal growth retardation [4, 5, 33–41] (Figure 2), but 
the detailed mechanism how imatinib interferes with bone metabolism and the final conse-
quences are not fully understood.
Regardless the type of kinase, imatinib binds to all structurally accessible ATP-binding 
pockets. Accordingly, other membrane-bound and cytosolic TKs, e.g., c-abl, PDGF-R α/β, 
c-KIT, and c-FMS [31, 42–44], are inhibited which play a major role in bone remodeling. 
Tyrosine kinase BCR-ABL1 c-abl c-Kit PDGF-Rα PDGF-Rβ c-FMS
IC
50
(µM) 0.25 0.19 0.15 0.10 0.39 1.42
IC, inhibitory concentration.
Table 1. Inhibitory effect of imatinib on selected TKs [31].
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Underlying dynamic processes of the growing skeleton are subject to strict regulation/com-
munication of bone formation and resorption and can be easily influenced by interfering 
factors. At present, it is not possible to study simultaneously these complex bone remodel-
ing processes such as the interaction of bone forming osteoblasts and bone resorbing osteo-
clasts by culturing systems in vitro. Therefore, it is only possible to study bone breakdown, 
bone structure, changes in the mineral content, and the overall structure of the bone in vivo 
in appropriate juvenile animal models.
In addition, TKI treatment for CML is not curative in most patients. Although first results from 
stopping TKI trials in adult patients after achieving sustainable deep molecular remission look 
promising most patients probably require a lifelong TKI treatment. This poses an increased 
risk to pediatric CML patients exposed to TKI treatment for decades as the long-term side 
effects on bone or other organs in a still growing organism presently are totally unknown.
4. Juvenile animal model for chronic TKI exposure
All regulatory authorities (Food and Drug Administration (FDA), Health Canada, European 
Medical Agency (EMA)) require animal tests to be conducted before humans are exposed to a 
new molecular entity. In drug developmental process, every potential new therapeutic agent 
Figure 2. Growth failure in pediatric CML patients during imatinib treatment [4]. SDS: Standard deviation score. One 
hundred and two patients (54 male/48 female; median age 12 years, range: 1–18 years) at diagnosis of CML receiving 
imatinib as upfront treatment were enrolled retrospectively in the trial CML-PAED II during the period 02/2006 to 
06/2014. Height standard deviation scores (SDS) were derived from WHO-AnthroPlus, version 1.04 software, a global 
growth-monitoring tool providing normal range values for the age cohorts from birth till 19 years. Eighty-one out of 
102 patients fulfilled the criteria for continuous assessment of growth scheduled at 3- months intervals during imatinib 
exposure. Twenty-one patients were analyzed at intervals ≠ 3 months. Calculation: Δ SDS = SDS
TKI therapy
–SDS
Diagnosis
; data 
are shown as Whiskers box plot (median ± 5th/95th percentile).
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has to pass clinical phase I-III studies in humans to verify safety, dosage, efficacy, side effects, 
and monitoring adverse reactions. All these studies are done in adult volunteers or adult 
patients if the disease under study occurs not exclusively at pediatric age [45]. Thus, in order 
to gain insight into side effects occurring specifically in the still growing organism during the 
preclinical research phase, in vivo studies in young growing animals are of main importance.
However, almost in all instances, primarily adult animal models are used in preclinical 
research (for reviews about the ongoing debate about animal models in clinical research see 
Refs. [46–48]). Adult animals were also used to study the influence of imatinib on the skeletal 
system [49, 50]. But as the growth process of the juvenile bone differs significantly from a 
mature bone, results described so far in adult patients/animals cannot readily be transferred 
to pediatric cohorts. Furthermore, Juvenile animal models cannot easily be selected as they 
are not established to match every single “research question” or disease on a routine basis.
Therefore, we describe here our established juvenile animal model to study side effects of a 
chronic exposure of imatinib primarily on the growing bone and to a lesser extent on other 
organs.
When establishing a juvenile animal model, several issues should be considered like the 
rodent species itself (mouse vs. rat), the strain (inbred vs. outbred), the overall speed of 
development (age when puberty starts), and convenient ways of drug administration in the 
situation of long-term exposure (intraperitoneal vs. subcutaneous vs. oral gavages vs. micro-
osmotic pumps). Overall, the developmental stages must be comparable to human life.
4.1. Mice versus rat
Most of the animals used in biomedical research are mice and rats because of their availabil-
ity, ease of handling, and fast reproduction rate. Mice are an excellent model for human dis-
eases because genetically they share 98% homology with human genome as well as a similar 
organization of their DNA and gene expression. However, the genome of a rat is smaller than 
its human equivalent but larger than that of a mouse.
Compared to mice, rats offer many advantages as, for example, their physiology is easier to 
monitor and is more like the corresponding human condition. But the most important advan-
tage of the rat is its bigger size, not just because of the added ease to perform surgical proce-
dures, but because of larger substructures (e.g., bone growth line, metaphysis) in organs thus 
influencing (i) which ratio of the organ is prone to an experimental lesion and (ii) the distance 
effects drugs exert to a specific anatomical area [51].
As we questioned about side effects of a chronic imatinib exposure on the growing organism, 
we were interested in the side effects on the long bones, which are much bigger in rats as 
compared to mice. As an additional benefit, we could also monitor side effects on other grow-
ing and developing organs like heart and testis as rats are a preferred model in cardiac and 
reproduction questions [52].
4.2. Inbred versus outbred strain
In general, the difference between outbred and inbred strains lies in their genetic background. 
Inbred strains are characterized by almost 99% homogeneity of the genome resulting from a 
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long inbreeding of this strain, whereas outbred strains have a diverse genetic background. 
Due to this genetic characteristic, animals of inbred strains react nearly identical to a specific 
intervention, like medical treatment, surgery, etc., wherefore the influence of this interven-
tion on a particular parameter can be identified more precisely. However, outbred strains 
reflect the natural situation more accurately as every individual is genetically different from 
the other. Every animal of an outbred strain will react slightly different to a specific interven-
tion, which discloses all possible effects of this intervention on the metabolism and mimics 
more the situation in the clinic. Therefore, depending on the experimental question and if 
you need a genetic diversity in your test population, inbred or outbred strains are used. Our 
study focused on side effects of long-term TKI treatment on bone remodeling and to mimic 
the human situation, we choose juvenile rats of the outbred strain “Wistar.”
4.3. Male versus female
We exclusively studied Wistar rats of male gender, as males tend to be more sensitive to bone 
influencing agents than female animals due to more rapid weight development and gender-
specific hormones.
Prepubertal young Wistar rats triple their body weight, regardless of sex, from about 60 to 
180 g in 14 days from the 3rd to 5th week of life due to the increasing growth hormone (GH) 
pulse amplitudes. The duration of GH pulses is significantly longer in males versus females, 
a pattern that continues throughout adulthood. Between 5th and 7th  week of life, GH pulse 
amplitudes are similarly increased in both sexes [53, 54]. The rapid skeletal growth associated 
with this is particularly strongly influenced by interfering factors. In postpuberty, the growth 
slows down, especially in female rats, who weigh 200 g in the 8th week of life and 220 g in the 
10th week of life. Contrary, male animals reach a body weight of 300 g postpubertally in the 
8th week of life and 390 g in the 10th week of life. These differences in growth dynamics should 
also make postpubertal bone alterations due to TKI exposure more prominent in male animals.
Nevertheless, additional factors especially endocrine changes in hormones, such as testoster-
one, 17ß-estradiol, and corticosterone, inducing and associated with the onset of puberty and 
puberty itself may be more important than GH to decide about the sex when setting up an ani-
mal model. It is commonly considered that puberty lasts until the 8th week of age [54]. However, 
onset of puberty in the rat (as measured by the age at vaginal opening and the onset of estrous 
cyclicity) occurs between 4th and 5th week in females, whereas in males (as measured by prepu-
tial separation which is an androgen-dependent event) occurs around 7th week of life depending 
on the strain used [55]. The onset of puberty in male Wistar rats based on the increase in plasma 
testosterone levels starts at 46–50 days of age and progressively increases until 76 days of age 
[56–58]. However, related to the increased production of estrogen and its positive influence on 
bone formation, trabecular bone density increases significantly both in women and in female 
rats with the onset of puberty [59, 60]. Because of this hormonal influence, effects on the bones, 
which are only mild, would be more difficult to detect in the female organism.
4.4. Drug administration
For chronic drug exposure, we choose administration via the drinking water. Drug appli-
cation via subcutaneous (s.c.) or intraperitoneal injection (i.p.) or oral gavage is the most 
Studying Side Effects of Tyrosine Kinase Inhibitors in a Juvenile Rat Model with Focus on Skeletal...
http://dx.doi.org/10.5772/intechopen.70006
317
accurate type of body weight-related exposure. However, young animals are prone to risks 
of injury and subsequent infection in the pharynx and/or esophagus [61, 62]. Micro-osmotic 
pumps could also be considered for s.c. administration but repeated implantation and 
removal of the pumps combined with the increased risk of infection should be taken into 
account [63]. For a detailed review of routes for chronic drug administration, see ref. [64]. 
However, due to the pharmacodynamics of the TKI, single shot by s.c. or i.p. administra-
tion would need at least two TKI applications daily over 10 weeks. Considering animal 
ethics as well as personal resources over several weeks including shifts on weekends, these 
numerous manipulations are hardly tolerable and affordable. For these reasons, the chosen 
intake of the drug via the drinking water was the most adequate and convenient form of 
chronic TKI exposure. Also, the stability of the TKIs in aqueous solution at room tempera-
ture facilitated this approach. Hence, the drug intake is dependent on the daily drinking 
volume considering age and associated body weight. Other possible interfering factors are 
loss of liquid when changing the water bottles or leaking water bottles and changes in the 
drinking behavior due to changes in the environment like fluctuation in the room tem-
perature or humidity, or social conflicts between the animals. To counteract this, the care 
of the experimental animals, the measuring of the drinking volume, and the determination 
of weight gain were always carried out on a fixed schedule and by identical staff members 
including weekends.
Age-dependent drinking behavior of mammals varies. According to body weight, higher 
volumes are ingested by younger animals [65, 66]. Furthermore, rodents show a circadian 
rhythm of their food and drinking water intake. About 80% of the maximum daily intake of 
liquids occur at night [64]. This allows the conclusion that by administration via the drinking 
water, a peak level was achieved during the night, comparable to the single administration in 
human patients during the daytime.
4.5. Developmental stages
Due to the well-documented developmental stages of the rat, it is possible to carry out a 
comparison with human developmental stages in order to interpret the generated data in an 
orientated manner (Table 2).
Developmental stages Rat Human
Weaning 3 weeks 6 months
Puberty 7 weeks 12–14 years
Adolescent 8–11 weeks 15–20 years
Adult >12 weeks >20 years
Death 2–3 years 70–80 years
Table 2. Developmental stages of rat and human [67].
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Considering the rapid maturation of the rats and the objective of examining the development 
(infancy, puberty, and young adulthood), we selected an exposure period of 10 weeks starting 
at 4 weeks of age.
Summing key issues in the juvenile animal model described, we chronically exposed 
healthy 4-week-old male Wistar rats to varying concentrations (low dose vs. high dose) 
of imatinib via drinking water over a period of 10 weeks while growing. We applied dif-
ferent treatment schedules to mimic possible new treatment strategies (continuous vs. 
intermittent). During the entire exposure time, the developmental stages from the end 
of weaning until young adolescence were covered (Figure 3). During ongoing imatinib 
exposure, a defined number of animals from each cohort were humanely sacrificed at 
prepubertal stage (age 6 weeks; after 2 weeks of exposure), at pubertal stage (age 8 weeks; 
after 4 weeks of exposure), and at postpubertal stage (age 14 weeks; after 10 weeks of 
exposure) [68].
5. Side effects of chronic imatinib treatment on growing bone
At defined time points of analysis (Figure 3), blood serum was collected to measure TKI con-
centration by high-performance liquid chromatography (HPLC), biochemical markers of 
bone turnover, and hormone levels by ELISA technique. Long bones (tibia and femur) and 
lumbar vertebrae L1–L4 were isolated to determine bone length, vertebral height, bone mass, 
Figure 3. Experimental design of the juvenile animal model.
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and strength by using quantitative computed tomography (pQCT), micro-computed tomog-
raphy (μCT), and biomechanical testing [68].
5.1. TKI serum concentration
Imatinib mean serum levels of 1600 and 5600 ng/mL were achieved by continuous drug 
exposure via the drinking water to either low or high dose, respectively [68]. These serum 
concentrations match well with therapeutic imatinib levels of pediatric patients ranging 
from 2000 to 8000 ng/mL on imatinib administered at doses of 260–570 mg/m2 daily [26], 
whereas in adult patients, serum levels in the range of ~1000–3400 ng/mL on imatinib doses 
of 400–600 mg daily were measured [69, 70]. Reflecting the half-life of imatinib in rats 
reported to be 12.3 h [71], serum levels of animals receiving high dose imatinib intermit-
tently were below the detection limit of the assay (10.0 ng/mL) when serum was collected at 
the end of a 4-day period without drug exposure.
5.2. Long bone length and bone quality
During growth, a 10-week exposure to imatinib caused a significant reduction of the long 
bone length dose-dependently (Figure 4) [68]. These findings match with clinical data in chil-
dren indicating that continuous administration of imatinib—even in high doses—does not 
result in a complete stop of growth, rather in a decelerated growth rate of the long bones [5, 
36, 38–41, 72]. During growth, pQCT analysis of the bones revealed significantly reduced 
Figure 4. Growth impairment of long bones by imatinib is dependent on the cumulative dose [68]. Prep: Prepubertal; 
Pub: Pubertal; Postpub: Postpubertal. Compared to controls, high dose imatinib (1000 mg/L daily) causes stronger 
longitudinal growth impairment than low dose exposure (500 mg/L daily). “On/off” exposure (3 days “on”, 4 days “off”) 
to high dose imatinib mitigates this effect. Of note, the cumulative dose resulting from 1000 mg/L administered “on/off” 
is approximately identical to 500 mg/L daily administered continuously. The resulting reduction in length reflects the 
cumulative dose administered.
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trabecular bone mineral density (BMD) by imatinib exposure. Analysis of the 3D trabecular 
structure by μCT emphasizes these findings by demonstration of reduced bone volume den-
sity in combination with reduced trabecular number and connectivity [68]. Furthermore, our 
findings also indicated unchanged cortical BMD and cortical thickness during growth dose- 
and time-independently, whereas the bone strength of the femora was decreased after long-
term exposure to high dose imatinib. This could be explained by decreased cross-sectional 
area, periosteal, and endosteal circumference of the femora, suggesting a blunted radial appo-
sitional bone growth [68]. With regard to pediatric patients, BMD measurements or increased 
fracture rates under long-term imatinib treatment are not published yet. However, intermit-
tent treatment of the high dose mitigated all bony side effects of the long bones, which might 
offer a new perspective for pediatric patients.
5.3. Vertebrae height and quality
Concerning lumbar vertebra, 10-week imatinib exposure significantly reduced vertebral 
height combined with reduced trabecular BMD dose-dependently, whereas total BMD, corti-
cal BMD, cross-sectional area, and cortical thickness were not affected [68, 73]. At the moment, 
only limited data are available on the effect of imatinib on vertebrae. In adult patients with 
CML, O´Sullivan et al. observed significantly increased lumbar spine BMD after 24 months 
of imatinib treatment as assessed by dual energy x-ray absorptiometry (DXA) [74], whereas 
Vandyke et al. observed unchanged BMD [75]. We predict from our animal model that ima-
tinib also alters vertebral properties, but not to the same extent as in long bones [68].
5.4. Bone turnover markers
The bone resorption marker tartrate-resistant acidic phosphatase (TRAP) revealed signifi-
cantly decreased serum levels under continuous imatinib exposure indicating reduced osteo-
clast activity at all developmental stages [68]. This is confirmed by in vitro studies showing 
that imatinib impairs osteoclastogenesis leading to diminished numbers of TRAP-positive 
osteoclasts [49, 76]. However, bone resorption marker C-terminal collagen cross-links (CTX-I) 
revealed by trend elevated serum levels prepubertally, but normal levels during the ongoing 
exposure time, indicating nearly unchanged osteoclast activity during growth [68]. This is 
consistent with data from pediatric patients with CML describing by trend elevated CTX-I 
levels prepubertally while on imatinib [77].
Under imatinib exposure, bone formation marker osteocalcin was decreased but procollagen 
type I (PINP) levels were by trend elevated, pointing to improved bone formation and min-
eralization [68]. In vitro assays using human isolated mesenchymal stem cells, primary rat 
osteoblasts, and mouse osteoblast-like cell line MC3T3-E1 revealed all increased mineraliza-
tion combined with reduced proliferation under therapeutic imatinib concentration [50].
However, bone turnover markers of pediatric patients with CML exhibited a biphasic response 
during imatinib therapy with increasing levels within the first 3 months of treatment and a 
significant decline during long-term treatment (Figure 5) [77, 78].
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Figure 5. Biphasic response (time period 1 [pink background], period 2 [brown background]) of bone remodeling to 
imatinib treatment in pediatric patients with CML. Data depicted from CML-PAED II study [78]. One hundred and 
nineteen patients (70 male/49 female, median age 12 years, range 1–18 years) received 260–340 mg imatinib/m2 daily 
within 1 week after diagnosis of CML (0). Up to 30 patients (range 20–30) out of this cohort could successfully be 
monitored repeatedly over a median period of 3 years for all parameters planned to be analyzed by collecting blood 
and urine for 3- months under appropriate circumstances. Assays were performed in a central laboratory as described 
previously [77]. Age normalized reference values were used as standard deviation scores (SDS).
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6. Non bone-related side effects of imatinib treatment
6.1. Growth hormone
Main length growth regulating factors at childhood and adolescence are GH and “insulin-like growth 
factor 1” (IGF-1), thyroid hormone (T3, T4), glucocorticoids, and sex hormones during puberty [79].
GH is secreted by pituitary somatotrophins in a pulsatile manner and acts on peripheral tis-
sues, either directly or indirectly, through the stimulation of IGF-1 synthesis and secretion 
[80–82]. As reported, the increase in body height during childhood is initiated by promoting 
chondrocyte proliferation and endochondral ossification in the growth plate or induction of 
osteoblastogenesis, leading to linear bone growth [80].
Owing to growth, children and/or adolescents going through puberty are particularly vul-
nerable to a possible GH deficiency (GHD) under long-term imatinib treatment [5, 41]. 
Mimicking those findings in children on imatinib treatment, the juvenile animal model dis-
closed significantly lowered serum levels of IGF-1 binding protein 3 (IGF-BP3)—a stable and 
more accurately measurable degradation product of IGF-1—at all concentrations applied 
and at all ages investigated [37, 83, 84]. Data of clinical studies in pediatric CML patients 
under TKI therapy revealed IGF-1 and IGFBP-3 levels almost exclusively in the very low or 
deep pathological range when compared to age-matched controls, independent of treatment 
duration [83, 84].
6.2. Vitamin D and bone
Within the bone remodeling cycle, vitamin D plays a crucial role by influencing the overall 
mineralization and bone turnover of the skeleton. The main effects of the active vitamin D 
metabolite 1.25(OH)
2
D
3
 comprises of stimulating the absorption of calcium/phosphorus from 
the gut to create optimal circumstances for bone mineralization, as well as stimulation of the 
osteoblast-mediated mineralization and osteoclast differentiation [85]. The consequences of 
vitamin D deficiency are secondary hyperparathyroidism and bone loss, leading to osteopo-
rosis and fractures, mineralization defects, which may lead to osteomalacia in the long-term, 
and muscle weakness, causing falls and fractures [86].
Hypophosphatemia, associated with low serum levels of 25-(OH)D
3
, 1.25(OH)
2
D
3
, calcium, 
and secondary hyperparathyroidism are known side effects in adult patients with CML 
under imatinib treatment [3]. An explanation for these findings is that imatinib directly stim-
ulates bone formation while restraining resorption, resulting in a net flux of calcium from 
extracellular fluid into bone, a decreased serum calcium level, and a compensatory rise in 
the level of parathyroid hormone, which causes phosphaturia and modest hypophosphate-
mia [50]. Pediatric patients with CML also exhibit moderate secondary hyperparathyroid-
ism in conjunction with pathologically low 25-(OH)D
3
 and 1.25(OH)
2
D
3
 levels but normal 
serum calcium and phosphate levels under imatinib therapy [77, 78]. Thereby these effects 
were independent of the duration of imatinib therapy, which underlined once again that 
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 regulation and compensatory mechanisms on the growing skeleton are different from those 
in the adult skeleton.
How imatinib interferes with vitamin D synthesis and metabolism is poorly understood yet. 
So far only one study investigated in vitro the effect of imatinib on keratinocytes yet and 
revealed a competitive inhibition of CYP27B1, a vitamin D hydroxylating enzyme, by ima-
tinib [87].
6.3. Fertility
TKs like c-kit and PDGF-R, which are inhibited “off-target” by imatinib, are involved not only 
in the bone remodeling process but also in the regulation of spermatogenesis [88], raising the 
question of testicular toxicities by imatinib treatment. Up to now, the influence of TKIs on the 
male reproductive endocrine system in pediatric patients with CML is still controversially 
discussed [89].
The first study in neonatal rats revealed that imatinib interferes with postnatal testicular 
development [90]. Investigations in the juvenile animal model starting at an older age 
(4 weeks) depicted unchanged testis weight but reduced testosterone levels under long-
term imatinib exposure until young adulthood. Inhibin B, a protein that is predominantly 
produced in the testis controlling follicle stimulating hormone (FSH) [91], did not sig-
nificantly differ from controls, at all doses, and by all application schemes tested [92]. A 
clinical study conducted in a small cohort of boys (age: 7.8–18.9 years) with CML receiv-
ing TKI treatment revealed testosterone and inhibin B levels within normal age-related 
reference ranges [83, 84, 92]. Therefore, severe testicular toxicity by imatinib seems to be 
unlikely.
However, a closer look on spermatogenesis in the juvenile animal model revealed that the 
spermatogenic cell counts were significantly decreased by high dose imatinib exposure 
(Figure 6). Additionally, during spermatogenesis cell cycle, the stage of the dominant cell pro-
portion was shifted to more immature stages. Low dose and intermittent imatinib exposure 
attenuated these findings. Interestingly, spermatogenic cell proliferation was significantly 
lowered at all imatinib doses applied [93]. Thus, a delayed negative effect of long-term ima-
tinib exposure on spermatogenesis cannot be excluded.
6.4. Cardiac side effects of TKI treatment
In the literature as well as indicated by the manufacturers in the specialist information, car-
diotoxic and vascular side effects of imatinib and the next-generation TKIs are of special con-
cern [94–99]. However, this primarily may play a role in older adult patients with CML (age 
> 65 years) under TKI treatment.
The juvenile animal model under discussion disclosed an increase in the relative heart 
weight ratio (= ratio of the heart weight to total body weight at sacrifice) under imatinib 
exposure. Another study found that imatinib treatment led to mitochondrial-dependent 
myocyte loss and cardiac dysfunction, occurring more severely in older mice, in part due to 
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an age- dependent increase in oxidative stress [100]. This suggests that cardiac monitoring of 
older patients receiving imatinib therapy may be especially warranted.
As cardiac side effects were also observed with the use of dasatinib, in the experiment con-
ducted with the juvenile animal model, this 2nd-generation TKI was tested for safety, efficacy, 
and dose response. Surprisingly, animals died spontaneously in a dose- and exposure time-
dependent manner (Figure 7). Data of the surviving animals that were sacrificed according 
to the experimental set-up schedule (Figure 3) disclosed—dependent on the cumulative dose 
administered—increased relative heart weights, impaired heart ejection fraction as assessed 
by echocardiography, and elevated brain natriuretic peptide (BNP) serum levels, an indicator 
of cardiac dysfunction [101]. Data of this unexpected high toxicity can be explained by the 
serum elimination half-life time of dasatinib which is rather short and in the range of 2–3 h in 
rodents [102]. As known from clinical data on treatment of CML by dasatinib, it is not manda-
tory to achieve steady state drug blood levels as the intracellular concentration of dasatinib 
is responsible for efficacy, which is sufficiently achieved by once daily drug administration. 
Initial trials in humans based on drug administration twice daily were characterized by high 
toxicity requiring treatment interruption or reduction to once daily dosing [103]. Thus, the 
juvenile rat model also mimics this situation as a continuous intake of small doses of dasatinib 
via the drinking water evidently is associated with higher toxicity.
Initially, inhibition of the c-abl kinase was assumed to be the reason for cardiac toxicity by TKI 
[94]. But an extensive in vitro study of 18 TKIs on myocytes showed that their relative ability 
to inhibit ABL1 or ABL2 did not correlate with myocyte damage, revealing that inhibition 
Figure 6. Number of proliferating testicular epithelium cells (Marker Ki67) in Wistar rats under imatinib exposure [93].
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of other kinases like MEK1 and MEK2 could be responsible for the cardiotoxicity. However, 
it was reported that all TKIs induce myocyte damage correlating with their kinase inhibitor 
selectivity [97]. So, we conclude that it might be prudent to carefully monitor cardiac function 
in still growing individuals with CML if treated with TKI continuously over long periods.
7. Hypothesized model of osseous damage and clinical relevance
7.1. Model of action of imatinib on bone remodeling
Despite the knowledge accumulated so far, the detailed mechanism how imatinib impairs bone 
remodeling and growth remains yet speculative. In in vitro studies, it was shown that imatinib 
impairs osteoblastogenesis as well as osteoclastogenesis revealing its effect on bone remodel-
ing [49, 50, 104, 105]. However, long bone growth is not only based on the balanced action of 
bone formation and bone resorption but also depends on the endochondral bone formation 
at the epiphyseal line of the long bones. Here, the column structure of the epiphyseal line, 
achieved and maintained by chondrocytes, is of main importance. In general, the epiphyseal 
line or growth plate is divided into different zones: reserve zone (RZ), proliferative zone (PZ), 
and the hypertrophic zone (HZ) followed by the primary spongiosa (PS)—the initial trabecular 
bone. The transition zone between HZ and PS is the osteochondral junction (OJ) (Figure 8A).
During growth, new cartilage is formed at one side of the epiphyseal growth plate and 
is gradually replaced by bone. The work by Nurmio et al. disclosed a disorganization of 
the epiphyseal line by imatinib treatment of neonatal rats (1–15 days old) (Figure 9) [106]. 
Figure 7. Survival rate of juvenile Wistar rats under chronic dasatinib exposure [101].
Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy326
Instead of the typical long, smooth proliferating chondrocyte columns at the epiphyseal line, 
a thin, disorganized layer of proliferative cells was detected after imatinib treatment result-
ing in a decreased thickness of PZ and increased the thickness of the HZ. This is in line 
with an in vitro study revealing an inhibitory effect of imatinib on chondrocyte proliferation 
[107]. Nurmio et al. also observed that imatinib treatment led to a bone resorption arrest and 
increased bone formation at the OJ [106].
However, combining our data [68] with data from Nurmio et al. [106] and Vandyke et al. [107], it 
can be hypothesized that imatinib exposure alters metabolism and remodeling of the growing bone 
in a temporal-spatial stepwise fashion (Figure 8B). In the first instance, migration, proliferation, and 
activity of chondrocytes will be impaired by imatinib leading to a disturbed organization of the 
growth plate impairing longitudinal bone growth [106]. Altered growth hormone secretion under 
imatinib treatment as shown before in the growing organism [39, 41, 83] may aggravate this growth 
impairment. Thereafter, ongoing drug exposure causes a spatial activity shifting of bone remodel-
ing: initially, the formation will be elevated and shifted to the area of the osteochondral junction, 
whereas the activity of bone resorption remains unchanged but will be spatially shifted to the distal 
area of the trabecular bone [106]. Finally, under long-term imatinib treatment, osteoblastogenesis 
and osteoclastogenesis will be impaired [104, 108], hampering bone remodeling during growth.
As an interesting approach, our juvenile animal model demonstrated that intermittent ima-
tinib exposure will ameliorate growth impairment in rats. The inhibitory effect is not irrevers-
ible and we assume that during the days “OFF” imatinib exposure catch-up growth occurred. 
Therefore, drug administration following a schedule with “days on drug” and “days off drug” 
might reduce some skeletal side effects in pediatric patients. A single trial in older adults has 
already proven that intermittent TKI treatment is sufficient to control CML once remission 
Figure 8. Schematic overview of physiologic bone growth (A) and under imatinib exposure (B). On the left side, 
longitudinal section of the epiphyseal line of a rodent proximal tibial metaphysis is depicted [109]. The epiphyseal plate 
separates the epiphysis from the metaphysis and is important for endochondral bone formation. The growth plate is 
divided into reserve zone (RZ), proliferative zone (PZ), and the hypertrophic zone (HZ). The transition of HZ to the 
primary spongiosa (PS)—the initial trabecular network formed after the vascular invasion and matrix calcification—is the 
osteochondral junction (OJ). Under physiological conditions, longitudinal growth occurs by endochondral ossification. 
In this process, new cartilage is formed at one side of the epiphyseal growth plate and is gradually replaced by bone. 
Chondrocytes of the growth plate are initially in a resting state in the RZ. They differentiate through proliferative and 
hypertrophic stages (PZ, HZ) as the growth plate moves past. This programmed differentiation pathway ends in cell 
death in the HZ and the replacement of cartilage by bone by osteoblasts in the OJ resulting in the PS. (For detailed 
review, see Ref. [110]).
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has been achieved [111, 112]. However, the length and frequency of intervals to allow catch-
up growth in children on TKI treatment still have to be defined and at least in our rat model, 
this approach did not recover the biomechanical strength of the long bones.
7.2. Clinical relevance
The established juvenile rat model mimics to a gross extent side effects of long-term TKI 
exposure on the growing bone in a developmental stage-dependent fashion. Impairment of 
longitudinal growth, as observed in children under imatinib treatment, could be unequivo-
cally modeled and confirmed.
Figure 9. Disorganization of the femoral epiphyseal line by long-term imatinib exposure. 2 μm sections of decalcified 
femora were stained with hematoxylin-eosin (magnification 100 ×). Controls show the typical “column” structure of the 
epiphyseal line and its physiological narrowing with increasing age. However, under imatinib exposure, the cellular 
architecture is more disorganized in a dose- and time-dependent manner.
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Our hypothesis of spatiotemporal shifting of skeletal formation and resorption under imatinib 
is supported by clinical observations of a biphasic reaction of corresponding osseous metabo-
lism serum markers in adult and pediatric patients with CML. In adult patients, an increase 
in bone formation occurred accompanied by elevated bone formation markers in the serum 
within the first months of therapy [74]. Pediatric CML patients display a biphasic response of 
bone formation and bone resorption by increasing levels within the first 3 months of imatinib 
treatment followed by a significant decline until 12 months of treatment (Figure 5) [77, 78].
Furthermore, we could show that long-term imatinib exposure may result in reduced bone 
strength possibly posing an elevated fracture risk in pediatric patients. Since 2001, adult CML 
patients are treated with imatinib but until now, no elevated fracture rates have been described 
in these patients [113]. As pediatric CML patients are treated with imatinib only since the 
beginning of this millennium, there is still no long-term experience. Our animal model also 
revealed that intermittent imatinib treatment mitigated skeletal effects on the growing bone, 
thus pointing toward a possibility to improve the risk-benefit ratio of long-term TKI exposure 
in pediatric patients. First clinical data in adults look promising but further studies must be 
carried out to determine whether the intermittent exposure is also sufficiently effective for the 
control of CML [111, 112]. Regarding pediatric patients, the results from the juvenile animal 
model and the clinical experience from adult patients with CML should be combined. This 
approach can be expected to harbor great potential in translational research.
8. Other animal models
The aim of the animal model described in this chapter was to evaluate side effects on bone 
remodeling rather than gaining further insight into the biology of CML (e.g., to study elemen-
tary mechanisms of CML disease progression) or on a more efficient antileukemic treatment 
exerted by new drugs (e.g., exploring why resistance develops under TKI therapy) [114, 115]. 
For these essential questions, the reader is kindly referred to the detailed body of literature on 
establishing and maintaining acute lymphatic or myeloid leukemic cells in xenograft models, 
transgenic models, and syngeneic models using a broad range of species [116–119], whereas 
mice are used mostly in orthotopic animal models [120–123].
Our research described, focused on the question how bone metabolism is affected by TKI 
treatment as an off-targeted side effect and therewith induced structural and mechanical 
osseous changes in healthy not-outgrown animals [124]. Bone remodeling has been studied 
in many species and resulted in the current available knowledge [125–131]. Evidently, the 
financial burden of animal maintenance and drug doses to be administered when sequelae 
of chronic exposure are investigated are much lower using small animals like mice and rats. 
Especially in these species, the time periods concerning defined stages of development are 
shorter, thus requiring drug exposure only for 2–3 months in order to mimic one to two 
decades in humans [132].
Most importantly, any intervention on the bone during chronic TKI exposure of the animals 
was minimized. Bone growth and repair is governed by regulatory mechanisms other than 
that of the outgrown organism. Therefore, the model described here differs principally from 
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experiments investigating bone healing and growth after surgical procedures performed on 
the skeleton (for a comprehensive review see Refs. [131, 133, 134]).
Ethical concerns in the last decades resulted in the establishment of studying bone growth 
and development preclinically in ex vivo cultures mostly making use of embryonic bone 
of mouse or rat strains [135, 136]. For an overview on conventional versus static versus 3D 
dynamic bioreactor models as well as a chorioallantoic membrane (CAM)-culture systems, 
the reader is kindly referred to a comprehensive review by Abubakar et al [137]. The composi-
tion of the nursing cell culture medium in these models is a crucial step. However, concerning 
TKIs whose metabolism in juvenile rodents is still poorly characterized and pleiotropically 
influences bone remodeling (e.g., impact on synthesis of growth hormone and insulin-like 
growth factor, liver metabolism, vitamin D metabolism, renal function, etc.) evidently not all 
components can be added to a cell culture medium mimicking correctly the in vivo situation. 
Therefore, our investigations had to be restricted to a genetically unchanged—“healthy”—
animal model to study the side effects of long-term TKI exposure on bone remodeling during 
growth and in addition on other developing organs.
9. Conclusion
Long-term toxicity resulting from off-target effects of TKIs can be assessed conveniently by 
administering TKIs via the drinking water to juvenile male Wistar rats over a prolonged 
period. During all developmental phases (prepubertal, puberty, postpubertal, and adult), 
drug blood levels are obtained corresponding to data in humans. The juvenile animal model 
disclosed reduced long bone length and diminished vertebral height combined with reduced 
bone mass density and reduced breaking strength dose-dependently after chronic exposure 
to imatinib. Thus, the juvenile animal model depicted here mimics perfectly clinical observa-
tions on osseous changes observed in pediatric patients with CML. Furthermore, intermittent 
exposure of the high TKI dose mitigated the skeletal side effect and therefore represented a 
possible treatment option for pediatric patients suffering from longitudinal growth retarda-
tion under imatinib therapy. The juvenile animal model might also be of value to predict 
sequelae of TKI treatment in other human organs following exposure over decades.
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